) had a strong oncology product portfolio led by Revlimid and
Abraxane. The portfolio was further strengthened in Feb 2013 with
the FDA approval of Pomalyst in combination with low-dose
dexamethasone for the treatment of relapsed and refractory multiple
myeloma (MM) patients who have received at least two prior
therapies (including Revlimid and Velcade). The EU approval of the
drug (trade name: Imnovid) was subsequently gained in Aug 2013.
Celgene, like many other companies, has showcased data on its
oncology candidates/drugs at the annual meeting of the European
Hematology Association (EHA). Last week, Celgene presented data
from a retrospective analysis of a phase III study (MM-003) on
Pomalyst/ Imnovid in the MM indication. The primary data from the
study was reported earlier.
Celgene stated in its press release that due to the evaluation
of the final progressive free survival analysis by the Independent
Data Monitoring Committee, more than half the patients treated with
high-dose dexamethasone during the study crossed over to receive
Pomalyst plus low-dose dexamethasone. The retrospective analysis
aimed at estimating the difference in overall survival between the
two arms of the study after adjusting for those patients who
After adjusting for the cross over, data from the retrospective
analysis revealed an overall survival of 12.7 months for the
combination of low-dose dexamethasone and Pomalyst as against 5.7
months for the combination of high-dose dexamethasone and Pomalyst.
We expect Pomalyst/ Imnovid, which recorded sales of $136 million
in the first quarter of 2014, to perform well and drive growth at
Celgene going forward.
At EHA, Celgene and partner
) also presented encouraging interim data from two studies in
patients with beta-thalassemia. The first study evaluated
sotatercept in transfusion-dependent and non-transfusion-dependent
beta-thalassemia patients. The second study evaluated another
pipeline candidate ACE-536 in the above patient population.
Celgene, a biopharmaceutical company, carries a Zacks Rank #2
(Buy). Better-ranked stocks in the healthcare sector include
). Both stocks carry a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research?
Today, you can download 7 Best Stocks for the Next 30 Days.
Click to get this free report
REGENERON PHARM (REGN): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
CELGENE CORP (CELG): Free Stock Analysis Report
ACCELERON PHARM (XLRN): Free Stock Analysis
To read this article on Zacks.com click here.